English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA phase 2 trial of a monoclonal antibody known as tulisokibart for moderate-to-severe ulcerative colitis (UC) showed promising results for those who have not responded to conventional inflammatory bowel disease (IBD) treatment. The results were reported Thursday, September 26, in The New England Journal of Medicine.
Tag: irritable bowel conditions
All FODMAPs aren’t created equal: working toward alternative diets to manage IBS
Two studies from Michigan Medicine may provide hope for patients with irritable bowel syndrome struggling to implement the traditional low-FODMAP diet.